FDA Grants Breakthrough Therapy Designation to Armata’s Phage Therapy for Complicated Staph Blood Infections

FDA awards Breakthrough Therapy designation to Armata’s AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA.